Genscript Biotech Corporation
GNNSF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $3 | $3 | $3 | $5 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $1 | $0 | $0 | $0 |
| Enterprise Value | $3 | $3 | $3 | $4 |
| Revenue | $1 | $0 | $1 | $0 |
| % Growth | 1,466.6% | -94.1% | 25.1% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 61.8% | -105.3% | 54.7% | 52.3% |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 40.3% | 567.6% | -21% | -11.5% |
| Net Income | -$0 | $3 | -$0 | -$0 |
| % Margin | -4.9% | 9,473% | -31.2% | -0.4% |
| EPS Diluted | -0.012 | 1.44 | -0.083 | -0.001 |
| % Growth | -100.8% | 1,841.2% | -9,088.9% | – |
| Operating Cash Flow | $0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |